Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial | Synapse
April 6, 2022Open Access
Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
Key Points
Key points are not available for this paper at this time.
Abstract
This study was registered with ClinicalTrial.gov ( NCT03229096 ).